ARTICLE | Clinical News
FPA144: Preliminary Phase I data
February 1, 2016 8:00 AM UTC
Preliminary data from 27 patients with solid tumors in the dose-escalation Part 1 of an open-label, U.S. Phase I trial showed that doses of up to 15 mg/kg IV FPA144 every 2 weeks were well tolerated w...